Form 4: Akari Therapeutics Director James R. Neal Acquires 8 Million Shares

Director James R. Neal of Akari Therapeutics Plc acquired 8,000,000 ordinary shares at a price of $0.00065 per share on January 9, 2025.

Summary

• On January 9, 2025, James R. Neal, a director of Akari Therapeutics Plc, acquired 8,000,000 ordinary shares.
• The purchase price was $0.00065 per ordinary share.
• Following the transaction, Mr. Neal directly owns 32,216,000 ordinary shares.
• The ordinary shares may be represented by American Depositary Shares, each representing 2,000 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a director's share purchase. While insider buying can be seen as positive, it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive sign.

Key Dates